MedTrace Logo

The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

NCT00539786 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-05-16

No results posted yet for this study

Summary

PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Proton pump inhibitor (rabeprazole)

Patients receives rabeprazole 20mg AM and 20mg PM for 14 days

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Poong-Lyul Rhee, MD. Ph.D · Samsung Medical Center, Sungkyunkwan University School of Medicine

Study Design

Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2011-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539786 on ClinicalTrials.gov